Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer (ELENI)
Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer: a Multicenter, National, Prospective Non-interventional Study
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Laura Serrer
- Telefonní číslo: +49761152420
- E-mail: eleni@iomedico.com
Studijní místa
-
-
-
Freiburg im Breisgau, Německo, 79110
- Nábor
- Praxis für interdisziplinäre Onkologie & Hämatologie
-
Kontakt:
- Patrick Marschner
- Telefonní číslo: +49761386870
- E-mail: klifo@onkologie-freiburg.de
-
Paderborn, Německo, 33098
- Nábor
- St. Louise Frauen- und Kinderklinik
-
Kontakt:
- Michael P Lux
- Telefonní číslo: +49 5251864121
- E-mail: M.Lux@vincenz.de
-
Ravensburg, Německo, 88212
- Nábor
- Gemeinschaftspraxis für Hämatologie und Onkologie
-
Kontakt:
- Thomas Decker
- Telefonní číslo: +49 751 366197-0
- E-mail: thomas.decker@onkonet.eu
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Signed and dated informed consent form
- Postmenopausal women
- Age ≥18 years
- Eastern Cooperative Oncology Group Performance Status (ECOG) < 2
- Locally advanced and/or metastatic ER+ HER2- breast cancer
- Histologically proven ER positivity (defined as ≥1% staining by immunohistochemistry (IHC))
- Histologically proven HER2 negativity (defined as a IHC0 or IHC1+ score by IHC or a negative result by in situ hybridization (ISH), optionally combined with a IHC2+ score)
- Disease progression following first line ET + CDKi
- No more than one prior ET line in the advanced/metastatic setting and intention for 2nd-line treatment with elacestrant according to current elacestrant SmPC as assessed by the treating physician (ESR1 testing can be done after inclusion)
- For patients with proven ESR1mut: Study inclusion the latest 2 weeks after start of elacestrant treatment
Exclusion Criteria
- Prior chemotherapy in the advanced/metastatic setting
- Contraindications according to elacestrant SmPC, except for ESR1 test result for patients included prior to ESR1 testing.
- Participation in an interventional clinical trial within 30 days prior to enrolment or simultaneous participation in an interventional clinical trial (except follow-up phase)
Studijní plán
Jak je studie koncipována?
Detaily designu
Počet skupin / kohort
Kohorty a intervence
Skupina / kohortaSkupina / kohorta |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
ESR1 wildtype
Patients with a ESR1 wildtype tumor
|
Treatment decision of investigator
|
|
ESR1 mutated
Patients with a ESR1 mutated tumor
|
According to the Summary of Product Characteristics (SmPC)
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change from baseline in EORTC global health scale
Časové okno: From Time of enrollment until month 11
|
Change from baseline quality of life (QoL) over time for the global health scale of the EORTC QLQ- C30 questionnaire The EORTC QLQ- C30 global health scale ranges from 0 to 100, with higher scores indicating better quality of life.
|
From Time of enrollment until month 11
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Hodnotit parametry rozhodování lékařů o léčbě pomocí dotazníku
Časové okno: Základní linie
|
Frekvence různých parametrů ovlivňujících volbu terapie; dotazník vyplněný ošetřujícím lékařem.
|
Základní linie
|
|
Time to deterioration in global health scale (EORTC QLQ-C30)
Časové okno: From Time of enrollment until month 11
|
Time to deterioration in global health scale of EORTC QLQ-C30 The EORTC QLQ- C30 global health scale ranges from 0 to 100, with higher scores indicating better quality of life.
|
From Time of enrollment until month 11
|
|
Time to deterioration in functional scores (EORTC QLQ-C30)
Časové okno: From Time of enrollment until month 11
|
Time to deterioration in functional scores of EORTC QLQ-C30.
The EORTC QLQ- C30 functional score ranges from 0 to 100, with higher scores indicating better quality of life.
|
From Time of enrollment until month 11
|
|
Time to deterioration in symptom scores (EORTC QLQ-C30)
Časové okno: From Time of enrollment until month 11
|
Time to deterioration in symptom scores of EORTC QLQ-C30 The EORTC QLQ- C30 symptom score ranges from 0 to 100, with lower scores indicating better quality of life.
|
From Time of enrollment until month 11
|
|
Change from baseline in functional and symptom scores
Časové okno: From Time of enrolment until up to 11 months after enrolment.
|
Change from baseline in functional and symptom scores of EORTC QLQ-C30 The EORTC QLQ- C30 functional and symptom scores ranges from 0 to 100, with higher scores indicating better quality of life (for functional scores), and lower indication better quality of life for symptom scores.
|
From Time of enrolment until up to 11 months after enrolment.
|
|
Change from baseline in visual analogue scale (VAS)
Časové okno: From Time of enrollment until month 11.
|
Change from baseline in EQ-5D-5L visual analogue scale (VAS); The EQ-5D-5L VAS ranges from 0 to 100, with higher scores indicating better quality of life.
|
From Time of enrollment until month 11.
|
|
Change from baseline in index value
Časové okno: From Time of enrollment until month 11.
|
Change from baseline in EQ-5D-5L Index Value The EQ-5D-5L index value ranges from -0.661 to 1, with higher scores indicating better quality of life.
|
From Time of enrollment until month 11.
|
|
Change from baseline in all scales of EQ-5D-5L
Časové okno: From Time of enrollment until month 11.
|
Change from baseline in all scales of EQ-5D-5L The scales of EQ-5D-5L range from 1 to 5, with lower scores indicating better quality of life.
|
From Time of enrollment until month 11.
|
|
Prevalence of ESR1 mutation
Časové okno: Baseline
|
Assess prevalence of ESR1mut in patients intended for elacestrant treatment as well as the testing methodology and results for ESR1 mutations.
|
Baseline
|
|
Drug safety: Frequency
Časové okno: From time of treatment start until 30 days after end of elacestrant treatment
|
Frequency of specific (serious) adverse drug reactions ((S)ADRs) (nausea, vomiting, decreased appetite)
|
From time of treatment start until 30 days after end of elacestrant treatment
|
|
Drug safety: Incidence of adverse events
Časové okno: From time of treatment start until 30 days after end of elacestrant treatment
|
Incidence of (serious) adverse events ((S)AEs), (serious) adverse drug reactions ((S)ADRs)
|
From time of treatment start until 30 days after end of elacestrant treatment
|
|
Drug safety: Change from baseline in AST (Aspartate Aminotransferase)
Časové okno: From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)
|
Change from baseline in AST
|
From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)
|
|
Drug safety: Change from baseline in ALT (Alanine Aminotransferase)
Časové okno: From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)
|
Change from baseline in ALT
|
From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)
|
|
Drug safety: Change from baseline in bilirubin
Časové okno: From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)
|
Change from baseline in bilirubin
|
From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)
|
|
Patients and disease characteristics: Age
Časové okno: Baseline
|
Assess patients characteristics in patients with intention for treatment with elacestrant: Age (descriptive statistics, categorical (</≥ 65))
|
Baseline
|
|
Patients and disease characteristics: Body mass index (BMI)
Časové okno: Baseline
|
Assess patients characteristics in patients with intention for treatment with elacestrant: BMI (descriptive statistics, categorical (underweight, normal weight, overweight, obese))
|
Baseline
|
|
Patients and disease characteristics: ECOG Performance status
Časové okno: Baseline
|
Assess patients characteristics in patients with intention for treatment with elacestrant: ECOG Performance status
|
Baseline
|
|
Patients and disease characteristics: CCI (Charlson score and contributing diseases)
Časové okno: Baseline
|
Assess patients characteristics in patients with intention for treatment with elacestrant: CCI (Charlson score and contributing diseases)
|
Baseline
|
|
Patients and disease characteristics: Time since diagnosis
Časové okno: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: Time since diagnosis (descriptive statistics)
|
Baseline
|
|
Patients and disease characteristics: TNM staging
Časové okno: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: TNM staging (including AJCC) at initial diagnosis
|
Baseline
|
|
Patients and disease characteristics: Metastatic sites
Časové okno: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: • Metastatic sites at inclusion
|
Baseline
|
|
Patients and disease characteristics: Tumor Grading
Časové okno: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: Tumor Grading at initial diagnosis and inclusion
|
Baseline
|
|
Patients and disease characteristics: HR and HER2 status
Časové okno: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: HR status and HER2 status at initial diagnosis and at inclusion
|
Baseline
|
|
Patients and disease characteristics: Prior adjuvant chemotherapy
Časové okno: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: Prior adjuvant chemotherapy
|
Baseline
|
|
Patients and disease characteristics: Prior adjuvant endocrine therapy
Časové okno: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: Prior adjuvant endocrine therapy
|
Baseline
|
|
Patients and disease characteristics: prior CDKi/endocrine therapy in the palliative setting
Časové okno: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: Type and duration of prior CDKi/endocrine therapy in the palliative setting (descriptive statistics, categorical ≤6 months / >6 months; ≤12 months / >12 months)
|
Baseline
|
|
Patients and disease characteristics: Disease site
Časové okno: At time of enrollment
|
Assess disease characteristics in patients with intention for treatment with elacestrant: Disease site (bone-only / visceral / non-visceral (not bone-only)) at inclusion
|
At time of enrollment
|
|
Patients and disease characteristics: concomitant diseases
Časové okno: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: concomitant diseases
|
Baseline
|
|
Use of concomitant medication
Časové okno: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
Assess the use of concomitant medication during treatment with elacestrant.
|
max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
|
Frequency of first subsequent systemic antineoplastic therapy for ESR1wt patients and ESR1mut patients without elacestrant treatment
Časové okno: max. 24 months; at patient patient-specific start of treatment
|
Assess second-line treatments for all patients by ESR1 status (Frequency of first subsequent systemic antineoplastic therapy for ESR1wt patients and ESR1mut patients without elacestrant treatment (refers to first treatment received starting from second line)
|
max. 24 months; at patient patient-specific start of treatment
|
|
Details on treatment with elacestrant: reason for end of treatment
Časové okno: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
Assess reason for end of treatment (treatment with elacestrant)
|
max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
|
Details on treatment with elacestrant: dose intensity
Časové okno: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
Assess dose intensity (treatment with elacestrant) as prescribed by the treating physician
|
max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
|
Details on treatment with elacestrant: frequency and type of dose modification
Časové okno: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
Assess Frequency and type of dose modifications (dose reductions, interruptions) compared to SmPC of elacestrant.
|
max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
|
Details on treatment with elacestrant: reasons for dose modifications and interruptions
Časové okno: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
Assess reasons for dose modifications and interruptions (elacestrant treatment)
|
max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
|
Treatments following elacestrant therapy: Type of first subsequent systemic antineoplastic therapy
Časové okno: max. 24 months; from the patient-specific end of elacestrant treatment until end of study
|
Details on treatments following elacestrant therapy (Type of first subsequent systemic antineoplastic therapy)
|
max. 24 months; from the patient-specific end of elacestrant treatment until end of study
|
|
Treatments following elacestrant therapy: Frequency of first subsequent systemic antineoplastic therapy
Časové okno: max. 24 months; from the patient-specific end of elacestrant treatment until end of study
|
Details on treatments following elacestrant therapy:Frequency of first subsequent systemic antineoplastic therapy for ESR1mut patients (refers to first treatment received after Elacestrant so starting from third line)
|
max. 24 months; from the patient-specific end of elacestrant treatment until end of study
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Thomas Decker, Professor, Gemeinschaftspraxis für Hämatologie und Onkologie GbR Ravensburg
- Vrchní vyšetřovatel: Michael Patrick Lux, Professor, St. Louise Frauen- und Kinderklinik Paderborn
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- IOM-090506
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .